Fed Circ says Indivior patent was anticipated
30-11-2021
Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute
25-08-2020
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29-08-2019
Piotr Swat / Shutterstock.com
The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Indivior, Dr Reddy’s, generics, Suboxone, opioid addiction, patent infringement, patent validity, US Court of Appeals for the Federal Circuit
